openPR Logo
Press release

Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: NKTR) announced

01-16-2020 07:47 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares.

An investigation on behalf of current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares.

An investigation was annpounced concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics.

Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: NKTR stocks, concerns whether certain Nektar Therapeutics directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that the Defendants failed to disclose to investors, that the Company did not comply with current good manufacturing practices, that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully, that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study, that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: NKTR) announced here

News-ID: 1898623 • Views: 526

More Releases from Shareholders Foundation

Investigation announced for Investors in NYSE: NOVA shares over potential Wrongd …
An investigation on behalf of investors in shares of Sunnova Energy International Inc. (NYSE: NOVA) was announced over potential breaches of fiduciary duties by certain officers and directors at Sunnova Energy International Inc. Investors who purchased shares of Sunnova Energy International Inc. (NYSE: NOVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Sunnova Energy
Investigation for Investors in E*TRADE Financial Corporation (NASDAQ: ETFC) over …
An investigation was announced concerning whether the takeover of E*TRADE Financial Corporation is unfair to NASDAQ: ETFC stockholders. Investors who purchased shares of E*TRADE Financial Corporation (NASDAQ: ETFC) and currently hold any of those NASDAQ: ETFC shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of E*TRADE Financial Corporation breached their
Investigation announced for Long Term Investors in shares of Altria Group, Inc. …
Certain directors of Altria Group, Inc are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in Altria Group, Inc. (NYSE: MO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NYSE: MO stocks follows a lawsuit filed against Altria Group, Inc. over alleged securities laws violations.
Investigation announced for Long-Term Investors in NASDAQ: MDXG shares over poss …
An investigation was announced concerning possible breaches of fiduciary duties by certain directors at MiMedx Group Inc. Investors who purchased shares of MiMedx Group Inc (NASDAQ: MDXG) and currently hold any of those NASDAQ: MDXG shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain MiMedx Group directors breached their fiduciary duties and caused damage

All 5 Releases


More Releases for NKTR

Dendrimers and Polymer Drugs Conjugate Market Detailed Study Analysis with Forec …
Dendrimers, and polymer drug conjugates are nano–sized medicines used for therapeutic applications. In polymer drug conjugates, polymers are covalently bonded to the drug molecule and the linkers are biologically active. Dendrimers are highly water soluble, polyvalent, and have precise molecular weight. They act as carriers of drugs, and facilitate their administration in the body. Dendrimers also have other applications in diagnostic analyses, target therapy, and vaccines. They are also used
Global Interleukin-2 Market - AbbVie Inc., Alkermes Plc, APT Therapeutics, Inc., …
According to a comprehensive study by KD Market Insights analyzes and forecasts the Interleukin-2 Market at both global and regional level. The report provides an analysis of 6 years, in which 2017 is the base year, 2018 as an estimated year and 2019-2023 is forecasted period. The report consists of overall market size in 2017 and its anticipated growth in further 6 years. It gives grasp about the high demanding
Global Opioids Market 2019 | Growth With Top Players: ALLERGAN, EGALET CORPORATI …
The global opioids market is expected to register a CAGR of nearly 5.0 % during the forecast period, 2018-2023. Opioid drugs obtained from the opium poppy plant are broadly classified into legally manufactured medications and illicit narcotics. The opioids market is primarily driven by rising palliative care facilities, and increasing prevalence of pain management. By region, owing to the rising adoption of opioids, growing geriatric patient population, and increasing demand
MedImmune Expert Speaker Interview released in run up to Immuno-Oncology Confere …
SMi Group reports: Exclusive interview with Grace Macaulay - MedImmune released in the run up to the Immuno-Oncology Conference, taking place on the 26 - 27 September 2018 in London. SMi is proud to host the inaugural Immuno-Oncology conference this Autumn on 26 - 27 September 2018 in London, UK, with a focus on propagating thought-provoking discussions on novel targeted cancer therapies. SMi Group caught up with expert speaker Grace Macaulay, Global
Nektar Therapeutics, Senior Vice President of Biology and Preclinical Developmen …
SMi Group has announced that Johnathan Zalevsky, Senior Vice President Biology & Preclinical Development, Nektar Therapeutics will be chairing day two of the 6th annual Cancer Vaccines conference, which will be taking place on September 27th & 28th 2017. Johnathan is an immunologist, responsible for the research portfolio at Nektar. Possessing extensive experience on the understanding of cellular and humoral immunity as it relates to vaccination technology and the purpose
Event Spotlight on Opioid Addiction at 17th Annual Pain Therapeutics Summit Feat …
SMi Group’s 17th Annual Pain Therapeutics conference will return to Central London on 22nd & 23rd May 2017 with an event spotlight on opioid addiction. Created with a scientific advisory board, the programme will hone in on new approaches to pain therapy and analgesic drugs, as well as look at the practicalities of using animal models and translational biomarkers in pain research. The spotlight on opioid addiction will feature 3 keynotes presenting